Episode 128: Debate of the Decade: RCTs in the Era of Precision Oncology
Healthcare Unfiltered
00:00
The Importance of Convince in RCTs
Chris Booth: To have a randomized control trial between arm A and arm B, you should be able to look your patient in the eye and tell him or her, I don't know if arm A or arm B are better. It's impossible to imagine that in RCTs, the phase three level, all the investigators think it's a 5050 chance the new drug is going to be better," he says. "We've been using targeted therapies for 20 years. Most of them either haven't worked"
Play episode from 16:56
Transcript
